Drug costs

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.

Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.

How can payers cope with new, ultra-expensive therapies?

While promising new options keep entering the scene, high costs can be problematic to patients and healthcare organizations. Here are some ways to cope.

Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.

Reference pricing models are emerging as increasingly popular approaches for lowering drug costs.

Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.

Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.

PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.

Autologous stem cell therapy may offer hope for patients with COPD. But some say caution is necessary.

CVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.

Here are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.

PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.

A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.

An eye-opening study by Precision for Value assesses cancer value frameworks.

An Avalere study has interesting findings about payer acceptance of biosimilars.

Analysts discuss how pharmacoeconomics will make a difference in treatment decisions.

The conference raised important points about unregulated growth opportunities and new pharmacy arena players.

Payers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.